Výsledky vyhledávání - Gabriel Etienne

Upřesnit hledání
  1. 1
    Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?

    Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy? Autor François‐Xavier Mahon, Gabriel Étienne

    Vydáno 2013
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Imatinib Mesylate and Gray Hair

    Imatinib Mesylate and Gray Hair Autor Gabriel Étienne, Pascale Cony‐Makhoul, François‐Xavier Mahon

    Vydáno 2002
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Evaluating gluteus maximus maximal voluntary isometric contractions for EMG normalization in male rugby players

    Evaluating gluteus maximus maximal voluntary isometric contractions for EMG normalization in male rugby players Autor Cochrane, Darryl J., Gabriel, Etienne, Harnett, Michael C.

    Vydáno 2019
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments

    Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments Autor Gutemberg Augusto Cruz dos Santos, Gabriel Etienne Brito de Salles, Milenna Grisoli Martins da Silva, Roxanne Cabral Cabral

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells

    Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells Autor Romain Gioia, Cédric Leroy, Claire Drullion, Valérie Lagarde, Gabriel Étienne, Stéphanie Dulucq, Éric Lippert, Serge Roche, François‐Xavier Mahon, Jean‐Max Pasquet

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories

    Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories Autor Régis Peffault de Latour, Jean Yves Mary, Célia Salanoubat, Louis Terriou, Gabriel Étienne, Mohamad Mohty, Sophie Roth, Sophie de Guibert, Sébastien Maury, J Cahn, Gèrard Socié

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

    Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Autor Stéphane Picard, Karine Titier, Gabriel Étienne, Emmanuelle Teilhet, Dominique Ducint, Marie‐Agnès Bernard, R. Lassalle, Gérald Marit, Josy Reiffers, Bernard Bégaud, Nicholas Moore, Mathiéu Molimard, François‐Xavier Mahon

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

    Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression Autor François‐Xavier Mahon, Sandrine Hayette, Valérie Lagarde, Françis Belloc, Béatrice Turcq, Franck E. Nicolini, Coralie Bélanger, Paul W. Manley, Cédric Leroy, Gabriel Étienne, Serge Roche, Jean‐Max Pasquet

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML

    Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML Autor Dorothée Selimoglu‐Buet, Bouchra Badaoui, Emmanuel Benayoun, Andréa Toma, Pierre Fenaux, Bruno Quesnel, Gabriel Étienne, Thorsten Braun, Nasséra Abermil, Margot Morabito, Nathalie Droin, Éric Solary, Orianne Wagner‐Ballon

    Vydáno 2017
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  10. 10
    The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

    The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity Autor Chloé James, Frédéric Mazurier, Sabrina Dupont, Ronan Chaligné, Isabelle Lamrissi‐Garcia, M Tulliez, Éric Lippert, François‐Xavier Mahon, Jean‐Max Pasquet, Gabriel Étienne, François Delhommeau, Stéphane Giraudier, William Vainchenker, Hubert de Verneuil

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

    Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy Autor Gabriel Étienne, Stéphanie Dulucq, Franck E. Nicolini, Stéphane Morisset, Marylise Fort, Anna Schmitt, M C Etienne, Sandrine Hayette, Éric Lippert, Caroline Bureau, Isabelle Tigaud, Didier Adiko, Gérald Marit, Josy Reiffers, François Xavier Mahon

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

    Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase Autor Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Dong‐Wook Kim, Gabriel Étienne, Gianantonio Rosti, Cármino Antônio De Souza, Mineo Kurokawa, Matt Kalaycio, Albert Hoenekopp, Xiaolin Fan, Yaping Shou, Hagop M. Kantarjian, Timothy P. Hughes

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia Autor Laurence Legros, Franck E. Nicolini, Gabriel Étienne, Philippe Rousselot, Delphine Réa, Stéphane Giraudier, Agnès Guerci‐Bresler, Françoise Huguet, Martine Gardembas, Martine Escoffre, Jean‐Christophe Ianotto, Marie‐Pierre Noël, Bruno Varet, Thomas Pagliardini, Isabelle Touitou, Stéphane Morisset, François‐Xavier Mahon

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Autor Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil, P. Le Coutre, Gabriel Étienne, Clarisse Lobo, Ricardo Pasqüini, Richard E. Clark, Andreas Hochhaus, Timothy P. Hughes, Neil J. Gallagher, Albert Hoenekopp, Mei Dong, Md Ariful Haque, Richard A. Larson, Hagop M. Kantarjian

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Mudanças comportamentais e resiliência dos estudantes de Medicina em meio à Pandemia da Covid-19 / Behavioral changes and resilience of medical students in the midst of the Covid-19 Pandemic

    Mudanças comportamentais e resiliência dos estudantes de Medicina em meio à Pandemia da Covid-19 / Behavioral changes and resilience of medical students in the midst of the Covid-1... Autor Gabriel Etienne Brito de Salles, Dominik Matsumoto Gandra, Heryda Pessôa Nogueira, Luísa Ceddia Porto Silva, Marina Caputo Cruz, Milena Gomes Corrêa, Nizia Railbolt Ferreira, Paula Berardinelli Bastos de Oliveira, Tales Rojas Zumak, Thablu Matheus Alves Gonzaga, Raquel Juliana de Oliveira Soares

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study

    Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study Autor Philippe Rousselot, Stéphane Prost, Joëlle Guilhot, Lydia Roy, Gabriel Étienne, Laurence Legros, Aude Charbonnier, Valérie Coiteux, Pascale Cony‐Makhoul, Françoise Huguet, Émilie Cayssials, Jean‐Michel Cayuela, Francis Relouzat, Marc Delord, Heriberto Bruzzoni‐Giovanelli, Laure Morisset, François‐Xavier Mahon, François Guilhot, Philippe Leboulch

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

    Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study Autor Maël Heiblig, Delphine Réa, Marie‐Lorraine Chrétien, Aude Charbonnier, Philippe Rousselot, Valérie Coiteux, Martine Escoffre‐Barbe, Viviane Dubruille, Françoise Huguet, Émilie Cayssials, Éric Hermet, Agnès Guerci‐Bresler, Shanti Amé, Lucila Sackmann‐Sala, Lydia Roy, Mohamad Sobh, Stéphane Morisset, Gabriel Étienne, Franck E. Nicolini

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

    Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial Autor Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, D-W Kim, Surapol Issaragrisil, Philipp D. le Coutre, Gabriel Étienne, P.E. Dorlhiac‐Llacer, Richard E. Clark, Ian W. Flinn, Hirohisa Nakamae, Breanne Donohue, Weiping Deng, Darshan Dalal, Hans D. Menssen, Hagop M. Kantarjian

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

    Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study Autor Delphine Réa, Guylaine Henry, Zena Khaznadar, Gabriel Étienne, François Guilhot, Franck E. Nicolini, Joëlle Guilhot, Philippe Rousselot, Françoise Huguet, Laurence Legros, Martine Gardembas, Viviane Dubruille, Agnès Guerci‐Bresler, Aude Charbonnier, Frédéric Maloisel, Jean‐Christophe Ianotto, Bruno Villemagne, François‐Xavier Mahon, Hélène Moins‐Teisserenc, Nicolas Dulphy, Antoine Toubert

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

    Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias Autor Franck E. Nicolini, Grzegorz Basak, Simona Soverini, Giovanni Martinelli, Michael J. Mauro, Martin C. Müller, Andreas Hochhaus, Charles Chuah, Inge Høgh Dufva, Giovanna Rege‐Cambrin, Giuseppe Saglio, Mauricette Michallet, Hélène Labussière, Stéphane Morisset, Sandrine Hayette, Gabriel Étienne, Eduardo Olavarría, Wei Zhou, Senaka Peter, Jane F. Apperley, Jorge E. Cortés

    Vydáno 2011
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: